Small Molecule Inhibition of Ligand-Stimulated RAGE-DIAPH1 Signal Transduction.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 26936329)

Published in Sci Rep on March 03, 2016

Authors

Michaele B Manigrasso1, Jinhong Pan2, Vivek Rai1, Jinghua Zhang1, Sergey Reverdatto2, Nosirudeen Quadri1, Robert J DeVita3, Ravichandran Ramasamy1, Alexander Shekhtman2, Ann Marie Schmidt1

Author Affiliations

1: Diabetes Research Program, Department of Medicine, New York University Langone Medical Center, 550 First Avenue, New York, 10016 New York, USA.
2: Department of Chemistry, University at Albany, State University of New York, 1400 Washington Avenue, Albany, 12222 New York, USA.
3: RJD Medicinal Chemistry and Drug Discovery Consulting LLC, 332 W. Dudley Avenue, Westfield, New Jersey 07090, USA.

Associated clinical trials:

Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease (STEADFAST) | NCT02080364

Articles cited by this

RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 8.55

Discovering high-affinity ligands for proteins: SAR by NMR. Science (1996) 7.10

RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04

Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem (1992) 5.60

RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14

N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem (1999) 3.72

Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest (2008) 3.11

A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest (2012) 2.98

Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem (1997) 2.53

Localizing the NADP+ binding site on the MurB enzyme by NMR. Nat Struct Biol (1996) 2.38

Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem (2008) 1.97

Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res (2008) 1.94

Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol (2001) 1.89

Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A (1994) 1.85

Advanced glycation end product recognition by the receptor for AGEs. Structure (2011) 1.84

Intrinsically disordered proteins are potential drug targets. Curr Opin Chem Biol (2010) 1.70

The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett (2003) 1.60

Structural basis for ligand recognition and activation of RAGE. Structure (2010) 1.50

S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J Biol Chem (2007) 1.49

Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation (2006) 1.48

RAGE Suppresses ABCG1-Mediated Macrophage Cholesterol Efflux in Diabetes. Diabetes (2015) 1.44

RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol (2008) 1.41

Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J Biol Chem (2006) 1.40

Formins in cell signaling. Biochim Biophys Acta (2008) 1.39

Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem (2001) 1.39

Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. PLoS One (2010) 1.38

Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci (2007) 1.32

Differences in proliferation of primary cultures of vascular smooth muscle cells taken from male and female rats. Blood Vessels (1980) 1.32

Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab (2013) 1.30

RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model. Am J Physiol Heart Circ Physiol (2008) 1.29

Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) (2010) 1.24

beta-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J Neurosci (1998) 1.22

S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J Biol Chem (2011) 1.22

TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding. PLoS One (2011) 1.21

Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J (2004) 1.19

RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes (2008) 1.18

Glucose regulates monocyte adhesion through endothelial production of interleukin-8. Circ Res (2003) 1.18

The 1.5 Å crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J Biol Chem (2010) 1.16

Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. Curr Protein Pept Sci (2005) 1.16

Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J Neurosci (2008) 1.15

Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int J Mol Sci (2013) 1.15

RAGE modulates hypoxia/reoxygenation injury in adult murine cardiomyocytes via JNK and GSK-3beta signaling pathways. PLoS One (2010) 1.15

Synchronous activation of ERK 1/2, p38mapk and PKB/Akt signaling by H2O2 in vascular smooth muscle cells: potential involvement in vascular disease (review). Int J Mol Med (2003) 1.14

The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol (2012) 1.12

Formins as effector proteins of Rho GTPases. Small GTPases (2014) 1.09

Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes (1997) 1.08

RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma. Cancer Res (2014) 1.08

Inhibiting protein-protein interactions using designed molecules. Curr Opin Struct Biol (2005) 1.07

Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway. FEBS Lett (2010) 1.07

RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice. Diabetes (2014) 1.05

Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1. J Biol Chem (2011) 1.04

The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs. Biochemistry (2014) 1.02

Formin mDia1 mediates vascular remodeling via integration of oxidative and signal transduction pathways. Circ Res (2012) 0.96

RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Res (2015) 0.94

Protection of ischemic hearts by high glucose is mediated, in part, by GLUT-4. Am J Physiol Heart Circ Physiol (2001) 0.92

Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory disease. Vascul Pharmacol (2015) 0.91

Simvastatin suppresses vascular inflammation and atherosclerosis in ApoE(-/-) mice by downregulating the HMGB1-RAGE axis. Acta Pharmacol Sin (2013) 0.90

Opposing roles of RAGE and Myd88 signaling in extensive liver resection. FASEB J (2011) 0.89

Receptor for advanced glycation end products in bacterial infection: is there a role for immune modulation of receptor for advanced glycation end products in the treatment of sepsis? Curr Opin Infect Dis (2012) 0.88

Critical role of RAGE and HMGB1 in inflammatory heart disease. Proc Natl Acad Sci U S A (2015) 0.87

Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway. Clin Pharmacol Ther (2015) 0.85

State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors. Chem Soc Rev (2015) 0.84

RAGE Mediates the Pro-Migratory Response of Extracellular S100A4 in Human Thyroid Cancer Cells. Thyroid (2015) 0.82

Circulating Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Biomarker of Emphysema and the RAGE Axis in the Lung. Am J Respir Crit Care Med (2015) 0.81

Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes. Diabetologia (2014) 0.79

The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes. Sci Rep (2015) 0.77

NMR characterization of the C-terminal tail of full-length RAGE in a membrane mimicking environment. J Biomol NMR (2012) 0.77

Inhibition of RAGE signaling through the intracellular delivery of inhibitor peptides by PEI cationization. Int J Mol Med (2013) 0.76